Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

Mariona Riudavets, MD, PhD; Arshid Azarine, MD, MSc; Sondes Smaali, MD; Young-Wouk Kim, MD; Vincent Thomas de Montpréville, MD; Alina Miruna Grecea, MD; Charles Naltet, MD; Annas Gazzah, MD; David Planchard, MD, PhD

JTO Clinical and Research Reports (Dec 2022)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

Mariona Riudavets, MD, PhD,
Arshid Azarine, MD, MSc,
Sondes Smaali, MD,
Young-Wouk Kim, MD,
Vincent Thomas de Montpréville, MD,
Alina Miruna Grecea, MD,
Charles Naltet, MD,
Annas Gazzah, MD,
David Planchard, MD, PhD

Affiliations

Mariona Riudavets, MD, PhD: Cancer Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France
Arshid Azarine, MD, MSc: Radiology Department, Groupe Hospitalier Paris Saint-Joseph, Paris, France
Sondes Smaali, MD: Cardiology Department, Gustave Roussy Cancer Campus, Villejuif, France
Young-Wouk Kim, MD: Radiology Department, Groupe Hospitalier Paris Saint-Joseph, Paris, France
Vincent Thomas de Montpréville, MD: Pathology Department, Hôpital Marie-Lannelongue, Le Plessis-Robinson, France
Alina Miruna Grecea, MD: Cancer Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France
Charles Naltet, MD: Cancer Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France
Annas Gazzah, MD: Cancer Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France
David Planchard, MD, PhD: Cancer Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France; Corresponding author. Address for correspondence: David Planchard, MD, PhD, Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114 Edouard Vaillant Street, F-94800, Villejuif, France.

Journal volume & issue: Vol. 3, no. 12
p. 100432

Abstract

Read online

Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new standard of care. Drug-related interstitial lung disease remains a serious unpredictable identified risk for patients treated with trastuzumab deruxtecan, requiring careful monitoring and multidisciplinary management. We report the first two cases of drug-related cardiotoxicity with acute myocarditis that developed after the first trastuzumab deruxtecan cycle. Routine cardiovascular risk screening is advisable, with close collaboration between cardiology specialists and oncologists.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords